Status:
NOT_YET_RECRUITING
Study on Ginkgo Biolba Extract Fifty and Mild Cognitive Impairment Associated With CSVD
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Mild Cognitive Impairment
Eligibility:
All Genders
50-75 years
Phase:
PHASE4
Brief Summary
This study aimed to explore the efficacy and safety of Ginkgo Biolba Extract fifty in treating mild cognitive impairment associated with cerebral small vessel disease (CSVD). Subjects included based o...
Eligibility Criteria
Inclusion
- Age 50-75 years old, with no limitation on sex.
- Head MRI showed SVD lesions. High white matter signal, Fazekas score ≥2 and meet one of the following requirements:
- Have ≥2 vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking); Combined lacunar foci; Combined with a new subcortical lacunar infarction (within 7 days of onset);
- Mild vascular cognitive impairment (memory and/or other cognitive domain abnormalities lasting for at least 3 months) with a score of 18 ≤MoCA score \< 26.
- Insufficient cognitive impairment to affect independence of life (mRS≤2).
- After enrollment, you can live in the local stable for more than two years.
- Sign the informed consent form.
Exclusion
- Known or suspected allergy to the components of the investigational drug or allergic constitution.
- With other brain diseases: Alzheimer's disease, Lewy body dementia, Parkinson's disease frontotemporal dementia, Crohn's disease, as well as other diseases that can lead to cognitive impairment, such as subdural hematoma, communicating hydrocephalus, brain tumors, drug poisoning, alcoholism, thyroid disease, and vitamin deficiency.
- Previous diagnosis of genetic/degenerative/inflammatory related small cerebral vascular diseases, such as CADASIL, CARASIL, etc.
- Concomitant with major depressive disorder (≥24 score in HAMD-17) or other transient organic psychosis (e.g., schizophrenia) that meets DSM-V criteria.
- Any medication used to treat cognitive impairment in the 4 weeks prior to randomization.
- Combined with severe neurological impairment, such as convenient hand hemiplegia, aphasia, auditory and visual impairment, the relevant examination or scale evaluation can not be completed.
- Combined with severe gastrointestinal diseases such as indigestion, gastrointestinal obstruction, gastric and duodenal ulcers that can affect drug absorption, or inability to swallow medication.
- Liver enzymes (ALT, AST)\>2 times the upper limit of normal value, creatinine\>1.2 times the upper limit of normal value, and decreased glomerular filtration rate (\<90ml/min).
- Life expectancy \< 1 year, or other reasons for not being able to complete follow-up.
- Pregnant or lactating women, or those with fertility plans.
- Has participated in other clinical trials.
Key Trial Info
Start Date :
September 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT06495476
Start Date
September 1 2024
End Date
June 30 2026
Last Update
August 28 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.